[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dm":81},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,64],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100600129",false,"NCT07093476","Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Trial and Open-Label Extension Study to Evaluate the Efficacy and Safety of Add-On Therapy With Empagliflozin for Patients With Inadequately Controlled Type 2 DiabetesMellitus in the Combination Treatment With Metformin and Alogliptin","Inclusion Criteria:\n\n* Adults at the time of signing the Informed Consent Form (ICF)\n* Signed the written ICF voluntarily after being fully informed of the objectives, methods, and effects of the study\n* Diagnosed with T2DM\n\nExclusion Criteria:\n\n* Diagnosed with other types of diabetes than T2DM\n* History of hypersensitivity reaction to the components or drugs of the same class as the IP or the background therapy\n* Uncontrolled severe complications of diabetes","ALL","19 Years",{"count":18,"type":19},171,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.",[25,26,27],"T2DM","Diabete Type 2","DM","RECRUITING","2025-08-07",{"date":31,"type":32},"2025-08-11","ACTUAL",{"date":34,"type":32},"2025-07-18",{"date":36,"type":19},"2027-04",{"name":38,"class":39},"Celltrion","INDUSTRY",1,{"id":42,"slug":4,"hasResults":10,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":10,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":20,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":40},"100356799","NCT03925701","Clinical Study Evaluating Vildagliptin Versus Vildagliptin\u002FMetformin on NAFLD With DM","Clinical Study Evaluating the Effectiveness of Vildagliptin Versus Vildagliptin\u002FMetformin on NAFLD With DM","Inclusion Criteria:\n\n* NAFLD and type 2 DM\n\nExclusion Criteria:\n\n* Viral hepatitis.\n* Child score more than 6.\n* renal impairment.","18 Years",{"count":49,"type":19},120,[22],"Clinical study evaluating vildagliptin versus vildagliptin\u002Fmetformin on NAFLD with DM.",[53],"dm","2019-04-26",{"date":56,"type":32},"2019-04-29",{"date":58,"type":32},"2019-04-01",{"date":60,"type":19},"2028-12",{"name":62,"class":63},"Sherief Abd-Elsalam","OTHER",{"id":65,"slug":4,"hasResults":10,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":10,"sex":15,"minAge":47,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":20,"phases":72,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":79,"leadSponsor":80,"locationsCount":40},"100356800","NCT03925714","Impact of P53 and SIRT1 in Type 2 Diabetes","Investigating the Impact of p53 and SIRT1 in the Development of Type 2 DM Through the Treatment of Prediabetic Individuals by Either Nigetella Salivata or Metformin","Inclusion Criteria:\n\n* Prediabetic subjects.\n\nExclusion Criteria:\n\n* Confirmed diabetes.\n* Hepatic or renal impairment.",{"count":71,"type":19},90,[22],"Investigating the impact of p53 and SIRT1 in the development of type 2 DM",[27],"2019-04-22",{"date":77,"type":32},"2019-04-24",{"date":58,"type":32},{"date":60,"type":19},{"name":62,"class":63},""]